U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20N2O7
Molecular Weight 388.3713
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARANIDIPINE, (S)-

SMILES

COC(=O)C1=C(C)NC(C)=C([C@H]1C2=C(C=CC=C2)[N+]([O-])=O)C(=O)OCC(C)=O

InChI

InChIKey=NCUCGYYHUFIYNU-KRWDZBQOSA-N
InChI=1S/C19H20N2O7/c1-10(22)9-28-19(24)16-12(3)20-11(2)15(18(23)27-4)17(16)13-7-5-6-8-14(13)21(25)26/h5-8,17,20H,9H2,1-4H3/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H20N2O7
Molecular Weight 388.3713
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

S-aranidipine or (S)-MPC-1304 is an enantiomer of MPC-1304 (methyl 2-oxopropyl 1,4-dihydro-2,6-di-methyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), a calcium entry blocker. The Ca2+ entry blocking activity of the (S) enantiomer of MPC-1304 was approximately 150 times greater than that of its (R) enantiomer. Likewise, the antihypertensive effect of the (S) enantiomer was twice as great as that of MPC-1304 (racemate) in conscious spontaneously hypertensive rats, while the (R) enantiomer was ineffective. Thus, most of the pharmacological activity of MPC-1304 resides in its (S) configuration.

Originator

Sources: Ohno, S., O. Komatsu, K. Mizukoshi, N. Akimatsu and N. Oda, 1991, Synthesis of metabolites of MPC-1304, a new calcium antagonist, and related compounds and optical resolution of MPC-1304 and related compounds, J. Pharmacobio-Dyn. 14, s-108
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8519282

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

0.1, 0.3 and 1 mg/kg p.o. (S)-MPC-1304 (S-aranidipine) showed marked hypotensive effects in conscious spontaneously hypertensive rats
Route of Administration: Oral
In Vitro Use Guide
(S)-MPC-1304 (S-aranidipine) inhibits calcium-induced contractions in the isolated rabbit aorta with IC50 values of 3.3 nM
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:07:35 GMT 2023
Edited
by admin
on Sat Dec 16 10:07:35 GMT 2023
Record UNII
D594X9Z4OS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARANIDIPINE, (S)-
Common Name English
(S)-MPC-1304
Code English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-, METHYL 2-OXOPROPYL ESTER, (S)-
Systematic Name English
Code System Code Type Description
PUBCHEM
25273590
Created by admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
PRIMARY
FDA UNII
D594X9Z4OS
Created by admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
PRIMARY
CAS
148372-44-5
Created by admin on Sat Dec 16 10:07:36 GMT 2023 , Edited by admin on Sat Dec 16 10:07:36 GMT 2023
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER